ABSTRACT

The coronavirus disease 2019 (COVID-19) has become the most critical healthcare issue worldwide since the pandemic was announced in March 2020. Although respiratory symptoms remain the critical characteristic feature of COVID-19 (with acute respiratory syndrome as the leading cause of mortality), the disease also affects other organs. In fact, the involvement of the cardiovascular system during COVID-19 may include acute coronary symptoms, acute heart failure and myocarditis, arrhythmias, cardiac tamponade, pulmonary embolism, and right ventricular failure due to a high-pressure mechanical ventilation. It is vital to note that all of the abovementioned disorders require specific, pandemic-adapted imaging algorithms. This brief review aims to discuss different cardiac imaging modalities to demonstrate their effectiveness in managing patients in the acute phase of COVID-19.

Introduction

Cardiovascular involvement among patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is common and significantly deteriorates the prognosis [1].

Hence, it requires quick diagnostic diagnosis and immediate treatment. In addition, several cardiac complications have been reported in the acute phase of COVID-19, such as myocarditis [2], pericarditis [3], acute myocardial infarction [4], stress-induced cardiomyopathy [5], cardiac tamponade [6], and/or right ventricular failure due to a high-pressure mechanical ventilation [7]. All these clinical situations require imaging techniques as a primary diagnostic tool.

Due to the sanitary regime during the COVID-19 pandemic, the availability of diagnostics may be
limited. Consequently, new or modified diagnostic pathways have recently been developed [8].

In this short review, we address the relevant issues concerning cardiovascular and pulmonary imaging, and share our experience from the COVID-19 ward.

**Computed tomography**

Computed tomography (CT) is the primary imaging tool in COVID-19 patients. In fact, high-resolution CT (HRCT) allows for the assessment of pulmonary involvement: pneumonia and pulmonary fibrosis. Typical images include bilateral, multifocal, multi-lane frosted glass with or without sub-segment consolidation, or a "crazy paving" pattern in the circumferential distribution. Results are usually presented as a percentage of infiltrating pulmonary parenchyma (Figure 1).

Furthermore, CT also plays a crucial role in diagnosing pulmonary embolism (PE). The prevalence of PE at the time of hospital admission for COVID-19 reached 14.2%, and further increased in the course of hospitalization [8]. By means of CT pulmonary angiography (CTPA) it is possible to confirm blood clots in the pulmonary arteries, or in the right heart chambers (Figure 2). The calculation of the right ventricle enlargement is a simple method to assess ventricular overload [9].

CT may constitute a helpful tool in the diagnosis of cardiovascular diseases and their complications, as on the basis of CT it is possible to exclude coronary artery disease (CAD) before further diagnosis [10], or before diagnosing an aortic pathology in patients with chest pain. Another issue is atrial fibrillation, the most common type of arrhythmia in COVID-19, observed in 17% of hospitalized patients. CT successfully replaces transoesophageal echocardiography in thrombus detection prior to cardioversion [11].

![Figure 1. High-resolution CT (HRCT) presenting a percentage of pulmonary infiltration during SARS-COV 2 infection: (a) large involvement – more than 80% of infiltration, (b) 60% infiltration, (c) about 30% infiltration](image1)

![Figure 2. Pulmonary embolism in the acute phase of COVID-19: (a) large embolus in the pulmonary trunk and pulmonary arteries, (b) small embolus in the right pulmonary artery, (c) embolus in the proximal part of the right low lobe artery](image2)
Concluding, CT in COVID-19 patients enables the application of “the triple rule-out principle” concerning all the aforementioned conditions (Table 1).

Serious limitations in the use of CT technique include transporting the patient to the radiology department under the appropriate sanitary regime and sanitation processes.

### Echocardiography

Although echocardiography is recommended as the first-line imaging tool for most cardiac conditions, it should not be routinely ordered in patients with COVID-19, particularly when no clinical benefits are expected. Transoesophageal echocardiography, which is an aerosol-generating procedure, should ideally be performed after the acute phase of COVID-19, due to an increased risk of virus transmission [12]. The primary echocardiographic modality in the management of COVID-19 patients is a point-of-care cardiac ultrasound (POCUS). Pocket size devices, such as a hand-held or a laptop-based scanner, are recommended, due to the speed of image availability, as well as bedside interpretation which allows reducing the scanning time and affects immediate patients’ management. Easy transportability and a more efficient disinfection play a vital role in comparison to large machines [13]. An echocardiogram targeted at a specific clinical problem is referred to as a focused cardiac ultrasound (FoCUS), and its main goals are presented in Table 2, whereas typical echocardiographic images are demonstrated in Figure 3.

Careful evaluation of the right ventricle (RV) may be crucial in mechanically ventilated patients. Echocardiographers should pay particular attention to high positive end-expiratory pressures (PEEP) – induced cardiopulmonary overload, resulting in the symptoms of acute cor pulmonale. In fact, a dilated right ventricle with a flattened interventricular septum with a basal RV to LV ratio >1.0 are the most specific echocardiographic markers identifying this process [14]. Moreover, McConnell’s sign, short RV outflow Doppler acceleration time, and high tricuspid regurgitation pressure gradient may indicate the presence of embolic material in pulmonary arteries [13,15]. In addition, POCUS may also play an essential role in the PE diagnosis in COVID-19 patients with contraindications for CT angiography (e.g. pregnant women, allergy to contrast media).

#### Table 1. “Triple rule-out” CT Angiography Objectives in COVID-19 patients presenting the acute chest pain

<table>
<thead>
<tr>
<th>The anatomical structure</th>
<th>Conditions which can be excluded by CT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thoracic aorta</td>
<td>Aortic dissection</td>
</tr>
<tr>
<td>Coronary arteries</td>
<td>CAD&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pulmonary arteries</td>
<td>PE&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Abbreviations: (a) coronary artery disease; (b) pulmonary embolism

#### Table 2. The focused cardiac ultrasound (FoCUS) parameters important in COVID-19 patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Left Ventricle</th>
<th>Right Ventricle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global Function</td>
<td>LVEF&lt;sup&gt;a&lt;/sup&gt;</td>
<td>RVFAC&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Regional Contraction Abnormalities</td>
<td>Hypo-/akinetic regions</td>
<td>Hypo-/akinetic regions</td>
</tr>
<tr>
<td>Diastolic Function</td>
<td>LVEDd&lt;sup&gt;c&lt;/sup&gt;</td>
<td>RVEDd&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Valves assessment</td>
<td>TRP&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>Pericardium thickening, pericardium effusion</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: (a) LVEF – left ventricular ejection fraction; (b) RVFAC – right ventricular fractional area change, (c) TAPSE – tricuspid annular plane systolic excursion; (d) ABS – apical ballooning syndrome (typical in the Tako-Tsubo syndrome); (e) LVEDd – left ventricular end-diastolic dimension; (f) RVEDd – right ventricular end-diastolic dimension; (g) TRP – tricuspid regurgitation pressure gradient
Lung point-of-care cardiac ultrasound (lung POCUS)

"Light beam" artifacts caused by subpleural consolidation can be early detected in COVID-19. They correspond to the "ground-glass" haze observed in CT imaging of COVID-19 pneumonia. The identification of the B lines in the POCUS examination may constitute an additional diagnostic value in tomography imaging [16,17].

Cardiac magnetic resonance (CMR)

CMR is currently considered the gold standard for tissue imaging in the assessment of myocardial oedema and fibrosis by late gadolinium enhancement [18]. It is vital to bear in mind that in patients with COVID-19 it allows to distinguish the non-ischemic myocarditis type (Figure 4) from the ischemic mechanism of a myocardial injury [19]. Furthermore, when coupled with T1 and T2...
mapping, CMR improves the diagnostic accuracy and identifies both acute and chronic changes of myocardial inflammation [20]. Interestingly, the most recent multicentre study has demonstrated that patients surviving severe COVID-19 who show elevated troponin levels and ongoing localised inflammation represent an emerging issue of clinical relevance. In patients with a severe COVID-19 course and a positive troponin assay, the evidence of residual inflammation on early CMR may play a role in the pathophysiology of dilated cardiomyopathy [19]. Nevertheless, a cost and availability issue for this technique may be a limiting factor for this modality.

Conclusions

The worldwide spread of SARS-CoV-2 disease revealed numerous weaknesses of healthcare systems, and changed our diagnostic pathways in patients suffering from COVID-19. Additionally, it also motivated the experts to create unique recommendations, algorithms, and practical guidelines to diagnose and treat infected patients, one of which is the employment of short protocols of cardiac imaging, which should be routinely applied due to the epidemic risk.

In our experience, CT may be selected as a "one-stop-shop" imaging method in COVID-19 patients, as it allows for obtaining various parameters in a single screening. Moreover, mobile devices, as well as POCUS and FoCUS protocols, should be the preferred choice when performing echocardiography, whereas CMR should be performed in troponin-positive patients, if available.

Acknowledgements

Conflict of interest statement
The authors declare no conflict of interest.

Funding sources
There are no sources of funding to declare.

References